A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma
Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label phase II, multicenter study. Eligible patients will receive CP-751,871
in monotherapy (20 mg/kg IV infusion on Day 1 of 3-week cycles). Tumor check-up will be
performed every 6-8 weeks. Treatment will be continued until disease progression or
unacceptable toxicities according to the patient or the investigator.
Phase:
Phase 2
Details
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain